

Heptahelical protein PQLC2 is a lysosomal cationic amino acid exporter underlying the action of cysteamine in cystinosis therapy

Adrien Jézégou^{a,b}, Elisa Llinares^c, Christine Anne^a, Sylvie Kieffer-Jaquinod^{d,e,f}, Seana O'Regan^a, Joëlle Aupetit^g, Allel Chabli^g, Corinne Sagné^a, Cécile Debacker^a, Bernadette Chadeaux-Vekemans^{g,h}, Agnès Journet^{d,e,f}, Bruno André^c, and Bruno Gasnier^{a,1}


^aUniversité Paris Descartes, Sorbonne Paris Cité, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8192, Centre Universitaire des Saints-Pères, F-75006 Paris, France; ^bEcole Doctorale 419, Université Paris-Sud 11, Hôpital Bicêtre, F-94276 Le Kremlin Bicêtre, France; ^cPhysiologie Moléculaire de la Cellule, Université Libre de Bruxelles, (ULB), B-6041 Gosselies, Belgium; ^dLaboratoire de Biologie à Grande Echelle, Institut de Recherches en Technologies et Sciences pour le Vivant, Commissariat à l'Energie Atomique-Grenoble, F-38054 Grenoble, France; ^eInstitut National de la Santé et de la Recherche Médicale, Unité 1038, F-38054 Grenoble, France; ^fUniversité Joseph Fourier, F-38000 Grenoble, France; ^gMetabolic Biochemistry, Hôpital Necker-Enfants Malades, F-75015 Paris, France; and ^hInstitut National de la Santé et de la Recherche Médicale Unité 747, Université Paris Descartes, Sorbonne Paris Cité, F-75006 Paris, France

AUTHOR SUMMARY

Transport of solute across membranes is crucial to eukaryotic cell physiology, as illustrated by diverse diseases associated with defective transport and the presence of ~400 solute transporter genes in humans. However, the function of many putative transporters remains unknown, such as the proteins responsible for lysosomal export of metabolites. Cystinosis, the lysosomal cystine exporter defective in cystinosis (1), is characterized by a duplicated motif termed the PQ loop. PQ-loop proteins are more frequent in eukaryotes than in prokaryotes, and, except for cystinosis, their molecular function remains unknown. The substrate-coupled proton-binding site is nested in the second PQ loop, suggesting that these motifs have functional significance (2). Here, we showed that another PQ-loop protein, PQLC2, is a lysosomal amino acid transporter that is relevant for the treatment of cystinosis.

We first showed that three yeast PQ-loop proteins of unknown function, Ypq1, Ypq2, and Ypq3, localize to the vacuolar membrane and are involved in homeostasis of cationic amino acids. Genetic inactivation of Ypq1 and Ypq2 decreases the sensitivity of yeast cells to canavanine, a natural toxic analog of arginine. This resistance phenotype requires prior accumulation of cationic amino acids in the vacuole. Moreover, transcription of the *YPQ3* gene is activated by lysine starvation. We thus hypothesized that Ypq1–3 proteins export cationic amino acids from the yeast vacuole.

We next identified PQLC2, a mammalian PQ-loop protein closely related to the yeast Ypq proteins, in purified lysosomal membranes. Because of the strong homology between PQLC2 and Ypq1–3, we reasoned that cationic amino acids are likely substrates. Indeed, frog oocytes expressing PQLC2 at their plasma membrane displayed robust transport activity that was



strongly activated in acidic extracellular medium (mimicking the lysosomal lumen) and exhibited narrow selectivity for cationic amino acids, including arginine, histidine, and lysine. Moreover, heterologous expression of PQLC2 at the vacuole of the yeast *ypq2* mutant restored canavanine sensitivity, and PQLC2 efficiently transported canavanine, suggesting that the increased canavanine sensitivity provided by PQLC2 results from increased vacuolar export. We concluded that PQLC2 and Ypq1–3 are evolutionarily conserved lysosomal/vacuolar exporters of cationic amino acids.

We next showed that PQLC2 exports from lysosomes a key chemical intermediate (cysteamine-cysteine mixed disulfide) underlying the current drug therapy of cystinosis, a rare inherited disease caused by mutations in the cystinosis gene. In this condition, large amounts of cystine accumulate in the patient's lysosomes (Fig. P1) and progressively impair the function of multiple organs, in-

cluding the kidney, endocrine glands, muscles, and CNS (1). The drug cysteamine (Cystagon) depletes cystine from cystinotic lysosomes and, with lifelong treatment, alleviates symptoms.

Author contributions: A. Jézégou, C.A., S.O., B.C.-V., A. Journet, B.A., and B.G. designed research; A. Jézégou, E.L., C.A., S.K.-J., S.O., J.A., A.C., C.S., C.D., B.A., and B.G. performed research; A. Jézégou, E.L., C.A., S.K.-J., S.O., B.C.-V., A. Journet, B.A., and B.G. analyzed data; and A. Journet, B.A., and B.G. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission.

¹To whom correspondence should be addressed. E-mail: bruno.gasnier@parisdescartes.fr.

See full research article on page E3434 of www.pnas.org.

Cite this Author Summary as: PNAS 10.1073/pnas.1211198109.

According to an early biochemical model (1), cysteamine reacts with lysosomal cystine and forms a lysine-like mixed disulfide that exits lysosomes through an unknown lysosomal transporter of cationic amino acids (Fig. P1). The elucidation of PQLC2 function prompted us to examine whether it corresponded to this mixed disulfide transporter. Using our frog oocyte assay, we found that PQLC2 efficiently transports the mixed disulfide. Moreover, silencing of the *PQLC2* human gene in cultured cells of patients trapped this intermediate when cells were exposed to cysteamine. We concluded that PQLC2 plays a key role in the therapeutic action of cysteamine.

Except for cystinosis, the molecular activity of other PQ-loop proteins remains unknown. The elucidation of PQLC2 function suggests that small-molecule transport is a conserved feature of the PQ-loop protein family, in agreement with the recent identification of SWEET sugar transporters (3) and of the mitochondrial pyruvate carrier (4, 5) in related protein families. The characterization of PQLC2 also has clinical implications.

Its role in cysteamine therapy of cystinosis should form the basis of rationales to improve this treatment and alleviate its constraints and side effects. For instance, allosteric or transcriptional activators of PQLC2 might potentiate cysteamine and help reduce the doses. The study of PQLC2 may also help clarify the origin of cationic amino acid abnormalities in Batten disease, another lysosomal disease characterized by early-onset neurodegeneration and the accumulation of “aging pigment” (lipofuscin) in lysosomes.

1. Gahl WA, Thoene JG, Schneider JA (2002) Cystinosis. *N Engl J Med* 347(2):111–121.
2. Ruivo R, et al. (2012) Mechanism of proton/substrate coupling in the heptahelical lysosomal transporter cystinosis. *Proc Natl Acad Sci USA* 109(5):E210–E217.
3. Chen LQ, et al. (2010) Sugar transporters for intercellular exchange and nutrition of pathogens. *Nature* 468(7323):527–532.
4. Herzig S, et al. (2012) Identification and functional expression of the mitochondrial pyruvate carrier. *Science* 337(6090):93–96.
5. Bricker DK, et al. (2012) A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, *Drosophila*, and humans. *Science* 337(6090):96–100.